Top

Published in:

01-12-2007 | Original Paper

Bone Morphogenetic Protein 7 is Elevated in Patients with Chronic Liver Disease and Exerts Fibrogenic Effects on Human Hepatic Stellate Cells

Authors: Frank Tacke, Erwin Gäbele, Frauke Bataille, Robert F. Schwabe, Claus Hellerbrand, Frank Klebl, Rainer H. Straub, Tom Luedde, Michael P. Manns, Christian Trautwein, David A. Brenner, Jürgen Schölmerich, Bernd Schnabl

Published in: Digestive Diseases and Sciences | Issue 12/2007

Abstract

Hepatic stellate cells (HSCs) are the main extracellular matrix (ECM)-producing cells in liver fibrogenesis. The excessive synthesis of ECM proteins deteriorates hepatic architecture and results in liver fibrosis and cirrhosis. This study investigated the role of bone morphogenetic protein 7 (BMP7) as a member of the transforming growth factor (TGF)-ß superfamily in chronic liver disease. Plasma levels of BMP7 were significantly elevated in patients with chronic liver disease compared with healthy controls. Immunohistochemistry of cirrhotic human liver demonstrated upregulated BMP7 protein expression in hepatocytes as compared with normal human liver. Because gene expression for all putative BMP7 receptors was induced during the culture activation process of primary human HSCs, we studied the effects of BMP7 on hTERT immortalized human HSCs in vitro. BMP7, as expressed and secreted after infection with adenoviruses encoding BMP7 (AdBMP7), increased proliferation of HSCs. The mRNA and protein expression of type I collagen and fibronectin was increased in BMP7-stimulated HSCs. Elevated systemic and hepatic levels of BMP7 in patients with chronic liver disease may contribute to progression of liver fibrogenesis in vivo.

Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113:685–700PubMedCrossRef

Sebald W, Nickel J, Zhang JL, Mueller TD (2004) Molecular recognition in bone morphogenetic protein (BMP)/receptor interaction. Biol Chem 385:697–710PubMedCrossRef

Zwijsen A, Verschueren K, Huylebroeck D (2003) New intracellular components of bone morphogenetic protein/Smad signaling cascades. FEBS Lett 546:133–139PubMedCrossRef

Miyazono K, Kusanagi K, Inoue H (2001) Divergence and convergence of TGF-beta/BMP signaling. J Cell Physiol 187:265–276PubMedCrossRef

Nohe A, Keating E, Knaus P, Petersen NO (2004) Signal transduction of bone morphogenetic protein receptors. Cell Signal 16:291–299PubMedCrossRef

Hu MC, Wasserman D, Hartwig S, Rosenblum ND (2004) p38MAPK acts in the BMP7-dependent stimulatory pathway during epithelial cell morphogenesis and is regulated by Smad1. J Biol Chem 279:12051–12059PubMedCrossRef

Wang SN, Lapage J, Hirschberg R (2001) Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol 12:2392–2399PubMed

Lee MJ, Yang CW, Jin DC, Chang YS, Bang BK, Kim YS (2003) Bone morphogenetic protein-7 inhibits constitutive and interleukin-1 beta-induced monocyte chemoattractant protein-1 expression in human mesangial cells: role for JNK/AP-1 pathway. J Immunol 170:2557–2563PubMed

Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115:209–218PubMedCrossRef

10.

Shen H, Huang G, Hadi M, Choy P, Zhang M, Minuk GY, Chen Y, Gong Y (2003) Transforming growth factor-beta1 downregulation of Smad1 gene expression in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 285:G539–546PubMed

11.

Schnabl B, Choi YH, Olsen JC, Hagedorn CH, Brenner DA (2002) Immortal activated human hepatic stellate cells generated by ectopic telomerase expression. Lab Invest 82:323–333PubMed

12.

Schnabl B, Purbeck CA, Choi YH, Hagedorn CH, Brenner DA (2003) Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype. Hepatology 37:653–664PubMedCrossRef

13.

Schnabl B, Bradham CA, Bennett BL, Manning AM, Stefanovic B, Brenner DA (2001) TAK1/JNK and p38 have opposite effects on rat hepatic stellate cells. Hepatology 34:953–963PubMedCrossRef

14.

Schwabe RF, Bradham CA, Uehara T, Hatano E, Bennett BL, Schoonhoven R, Brenner DA (2003) c-Jun-N-terminal kinase drives cyclin D1 expression and proliferation during liver regeneration. Hepatology 37:824–832PubMedCrossRef

15.

Franceschi RT, Wang D, Krebsbach PH, Rutherford RB (2000) Gene therapy for bone formation: in vitro and in vivo osteogenic activity of an adenovirus expressing BMP7. J Cell Biochem 78:476–486PubMedCrossRef

16.

Neumann E, Judex M, Kullmann F, Grifka J, Robbins PD, Pap T, Gay RE, Evans CH, Gay S, Scholmerich J, Muller-Ladner U (2002) Inhibition of cartilage destruction by double gene transfer of IL-1Ra and IL-10 involves the activin pathway. Gene Ther 9:1508–1519PubMedCrossRef

17.

Hellerbrand C, Jobin C, Iimuro Y, Licato L, Sartor RB, Brenner DA (1998) Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor. Hepatology 27:1285–1295PubMedCrossRef

18.

Schnabl B, Kweon YO, Frederick JP, Wang XF, Rippe RA, Brenner DA (2001) The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology 34:89–100PubMedCrossRef

19.

Yanagisawa M, Takizawa T, Ochiai W, Uemura A, Nakashima K, Taga T (2001) Fate alteration of neuroepithelial cells from neurogenesis to astrocytogenesis by bone morphogenetic proteins. Neurosci Res 41:391–396PubMedCrossRef

20.

Wordinger RJ, Agarwal R, Talati M, Fuller J, Lambert W, Clark AF (2002) Expression of bone morphogenetic proteins (BMP), BMP receptors, and BMP associated proteins in human trabecular meshwork and optic nerve head cells and tissues. Mol Vis 8:241–250PubMed

21.

Kim IY, Lee DH, Lee DK, Kim BC, Kim HT, Leach FS, Linehan WM, Morton RA, Kim SJ (2003) Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells. Clin Cancer Res 9:6046–6051PubMed

22.

Vanttinen T, Kuulasmaa T, Liu J, Voutilainen R (2002) Expression of activin/inhibin receptor and binding protein genes and regulation of activin/inhibin peptide secretion in human adrenocortical cells. J Clin Endocrinol Metab 87:4257–4263PubMedCrossRef

23.

Fujii S, Maeda H, Wada N, Kano Y, Akamine A (2006) Establishing and characterizing human periodontal ligament fibroblasts immortalized by SV40T-antigen and hTERT gene transfer. Cell Tissue Res 324:117–125PubMedCrossRef

24.

Borghi R, Vene R, Arena G, Schubert D, Albini A, Tosetti F (2003) Transient modulation of cytoplasmic and nuclear retinoid receptors expression in differentiating human teratocarcinoma NT2 cells. J Neurochem 84:94–104PubMedCrossRef

25.

Rothhammer T, Poser I, Soncin F, Bataille F, Moser M, Bosserhoff AK (2005) Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res 65:448–456PubMed

26.

Schnabl B, Hu K, Muhlbauer M, Hellerbrand C, Stefanovic B, Brenner DA, Scholmerich J (2005) Zinc finger protein 267 is up-regulated during the activation process of human hepatic stellate cells and functions as a negative transcriptional regulator of MMP-10. Biochem Biophys Res Commun 335:87–96PubMedCrossRef

27.

Hu K, Fink M, Froh M, Gabele E, Hellerbrand C, Muhlbauer M, Wiest R, Scholmerich J, Schnabl B (2005) Characterization of the human zinc finger protein 267 promoter: Essential role of nuclear factor Y. Biochim Biophys Acta 1729:14–23PubMed

28.

Tacke F, Brabant G, Kruck E, Horn R, Schoffski P, Hecker H, Manns MP, Trautwein C (2003) Ghrelin in chronic liver disease. J Hepatol 38:447–454PubMedCrossRef

29.

Lepreux S, Bioulac-Sage P, Gabbiani G, Sapin V, Housset C, Rosenbaum J, Balabaud C, Desmouliere A (2004) Cellular retinol-binding protein-1 expression in normal and fibrotic/cirrhotic human liver: different patterns of expression in hepatic stellate cells and (myo)fibroblast subpopulations. J Hepatol 40:774–780PubMedCrossRef

30.

Dorai H, Vukicevic S, Sampath TK (2000) Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol 184:37–45PubMedCrossRef

31.

Zeisberg M, Shah AA, Kalluri R (2005) Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J Biol Chem 280:8094–8100PubMedCrossRef

32.

Gould SE, Day M, Jones SS, Dorai H (2002) BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells. Kidney Int 61:51–60PubMedCrossRef

33.

Hruska KA, Guo G, Wozniak M, Martin D, Miller S, Liapis H, Loveday K, Klahr S, Sampath TK, Morrissey J (2000) Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am J Physiol Renal Physiol 279:F130–143PubMed

34.

Vukicevic S, Basic V, Rogic D, Basic N, Shih MS, Shepard A, Jin D, Dattatreyamurty B, Jones W, Dorai H, Ryan S, Griffiths D, Maliakal J, Jelic M, Pastorcic M, Stavljenic A, Sampath TK (1998) Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J Clin Invest 102:202–214PubMedCrossRef

35.

Morrissey J, Hruska K, Guo G, Wang S, Chen Q, Klahr S (2002) Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function. J Am Soc Nephrol 13:S14–21PubMedCrossRef

36.

Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R (2003) BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9:964–968PubMedCrossRef

37.

Lin J, Patel SR, Cheng X, Cho EA, Levitan I, Ullenbruch M, Phan SH, Park JM, Dressler GR (2005) Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease. Nat Med 11:387–393PubMedCrossRef

38.

Flechtenmacher J, Huch K, Thonar EJ, Mollenhauer JA, Davies SR, Schmid TM, Puhl W, Sampath TK, Aydelotte MB, Kuettner KE (1996) Recombinant human osteogenic protein 1 is a potent stimulator of the synthesis of cartilage proteoglycans and collagens by human articular chondrocytes. Arthritis Rheum 39:1896–1904PubMedCrossRef

39.

Nishida Y, Knudson CB, Eger W, Kuettner KE, Knudson W (2000) Osteogenic protein 1 stimulates cells-associated matrix assembly by normal human articular chondrocytes: up-regulation of hyaluronan synthase, CD44, and aggrecan. Arthritis Rheum 43:206–214PubMedCrossRef

40.

Soder S, Hakimiyan A, Rueger DC, Kuettner KE, Aigner T, Chubinskaya S (2005) Antisense inhibition of osteogenic protein 1 disturbs human articular cartilage integrity. Arthritis Rheum 52:468–478PubMedCrossRef

41.

Maliakal JC, Asahina I, Hauschka PV, Sampath TK (1994) Osteogenic protein-1 (BMP-7) inhibits cell proliferation and stimulates the expression of markers characteristic of osteoblast phenotype in rat osteosarcoma (17/2.8) cells. Growth Factors 11:227–234PubMed

42.

Tsai AD, Yeh LC, Lee JC (2003) Effects of osteogenic protein-1 (OP-1, BMP-7) on gene expression in cultured medial collateral ligament cells. J Cell Biochem 90:777–791PubMedCrossRef

43.

Ebara S, Nakayama K (2002) Mechanism for the action of bone morphogenetic proteins and regulation of their activity. Spine 27:S10–15PubMedCrossRef

Title: Bone Morphogenetic Protein 7 is Elevated in Patients with Chronic Liver Disease and Exerts Fibrogenic Effects on Human Hepatic Stellate Cells
Authors: Frank Tacke
Erwin Gäbele
Frauke Bataille
Robert F. Schwabe
Claus Hellerbrand
Frank Klebl
Rainer H. Straub
Tom Luedde
Michael P. Manns
Christian Trautwein
David A. Brenner
Jürgen Schölmerich
Bernd Schnabl
Publication date: 01-12-2007
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 12/2007
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-007-9758-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2007

Hepatobiliary Sarcoidosis Presenting as Sclerosing Cholangitis: Long-Term Follow-Up

Combination of Adrenaline Injection and Detachable Snare Application as Haemostatic Preventive Measures, Before Polypectomy of Large Colonic Polyps in Children

Successful Treatment of Acute Pancreatitis with Hydrocortisone in a Patient Postadrenalectomy

Clinical Course of Hepatitis B Virus Infection in Renal Allograft Recipients

Cutaneous Necrotizing Vasculitis Associated with Hepatitis C Virus Infection

Multiple Myeloma Presenting as Gastric Polyposis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials